Pethidine is indicated for the treatment of moderate to severe pain, and is delivered as a hydrochloride salt in tablets, as a syrup, or by intramuscular, subcutaneous or intravenous injection. For much of the 20th century, pethidine was the opioid of choice for many physicians; in 1975 60% of doctors prescribed it for acute pain and 22% for chronic severe pain.
Compared to morphine, pethidine was thought to be safer, carry a lower risk of addiction and to be superior in treating the pain associated with biliary spasm or renal colic due to its putative anticholinergic effects. It was later discovered that these were all myths and that it carried an at least equal risk of addiction, possessed no advantageous effects on biliary spasm or renal colic compared to other opioids and that, due to its toxic metabolite, norpethidine, it was more toxic than other opioids, especially during long-term use. It was also discovered that the norpethidine metabolite had serotonergic effects which means that pethidine could, unlike most opioids, contribute to serotonin syndrome.
Pethidine was once widely used as an analgesic in labour and delivery, but is now seldom used for this indication due to its numerous disadvantages over other opioids, namely, its potential drug interactions (especially with serotonergics) and its neurotoxic metabolite, norpethidine.
The adverse effects of pethidine administration are primarily those of the opioids as a class: nausea, vomiting, sedation, dizziness, diaphoresis, urinary retention and constipation. Unlike other opioids, it does not cause miosis. Overdosage can cause muscle flaccidity, respiratory depression, obtundation, cold and clammy skin, hypotension and coma. A narcotic antagonist such as naloxone is indicated to reverse respiratory depression. Serotonin syndrome has occurred in patients receiving concurrent antidepressant therapy with selective serotonin reuptake inhibitors or monoamine oxidase inhibitors. Convulsive seizures sometimes observed in patients receiving parenteral pethidine on a chronic basis have been attributed to accumumulation in plasma of the metabolite norpethidine (normeperidine). Fatalities have occurred following either oral or intravenous pethidine overdosage.
Pethidine has serious interactions that can be dangerous with monoamine oxidase inhibitors (e.g., furazolidone, isocarboxazid, moclobemide, phenelzine, procarbazine, selegiline, tranylcypromine). Such patients may suffer agitation, delirium, headache, convulsions, and/or hyperthermia. Fatal interactions have been reported including the death of Libby Zion. It is thought to be caused by an increase in cerebral serotonin concentrations. It is probable that pethidine can also interact with a number of other medications, including muscle relaxants, some antidepressants, benzodiazepines, and ethanol.
Pethidine's apparent in vitro efficacy as an antispasmodic agent is due to its local anesthetic effects. It does not have antispasmodic effects in vivo. Pethidine also has stimulant effects mediated by its inhibition of the dopamine transporter (DAT) and norepinephrine transporter (NET). Because of its DAT inhibitory action, pethidine will substitute for cocaine in animals trained to discriminate cocaine from saline.
It is more lipid-soluble than morphine, resulting in a faster onset of action. Its duration of clinical effect is 120–150 minutes although it is typically administered at 4–6 hour intervals. Pethidine has been shown to be less effective than morphine, diamorphine, or hydromorphone at easing severe pain, or pain associated with movement or coughing.
Like other opioid drugs, pethidine has the potential to cause physical dependence or addiction. Pethidine may be more likely to be abused than other prescription opioids, perhaps because of its rapid onset of action. When compared with oxycodone, hydromorphone, and placebo, pethidine was consistently associated with more euphoria, difficulty concentrating, confusion, and impaired psychomotor and cognitive performance when administered to healthy volunteers. The especially severe side effects unique to pethidine among opioids—serotonin syndrome, seizures, delirium, dysphoria, tremor—are primarily or entirely due to the action of its metabolite, norpethidine.
Pethidine is quickly hydrolysed in the liver to pethidinic acid and is also demethylated to norpethidine, which has half the analgesic activity of pethidine but a longer elimination half-life (8–12 hours); accumulating with regular administration, or in renal failure. Norpethidine is toxic and has convulsant and hallucinogenic effects. The toxic effects mediated by the metabolites cannot be countered with opioid receptor antagonists such as naloxone or naltrexone and are probably primarily due to norpethidine's anticholinergic activity probably due to its structural similarity to atropine, though its pharmacology has not been thoroughly explored. The neurotoxicity of pethidine's metabolites is a unique feature of pethidine compared to other opioids. Pethidine's metabolites are further conjugated with glucuronic acid and excreted into the urine.
In data from the U.S. Drug Abuse Warning Network, mentions of hazardous or harmful use of pethidine declined between 1997 and 2002, in contrast to increases for fentanyl, hydromorphone, morphine, and oxycodone. The number of dosage units of pethidine that were reported lost or stolen in the U.S. increased 16.2% between 2000 and 2003, from 32,447 to 37,687.
This article uses the terms "hazardous use", "harmful use", and "dependence" in accordance with Lexicon of alcohol and drug terms published by the World Health Organization (WHO) in 1994. In WHO usage, the first two terms replace the term "abuse" and the third term replaces the term "addiction".
The first QSAR focused on exploring how changing the nature of the aromatic substituents alters monoamine reuptake inhibitor affinities.
Nitrile Precursors → Pethidine/Analogs Ki & IC50, μM
? → 0.413
? → 17.8
? → 12.6
10.1 → 0.308
45% → 10.7
8% → 47%
5.11 → 0.277
22.0 → 4.10
36% → 26.9
0.430 → 0.0211
8.34 → 3.25
36.7 → 11.1
13.7 → 1.61
41.8 → 12.4
22% → 76.2
0.805 → 0.0187
2.67 → 0.125
11.1 → 1.40
0.125 → 0.0072
2.36 → 1.14
21.8 → 11.6
Mean ± SEM of 3 experiments in triplicate. % inhibition @ 100μM
Particular emphasis needs to be placed on the ↑ D/S of the p-iodo and β-Naph analogs.
p-I, D/S = 155
BN, D/S = 158
In behavioral activity studies, none of the compounds would substitute for cocaine in mice, and they were also inactive as LMA stimulants.
This is in direct contrast to the methylphenidate analogs which more convincingly displayed cocaine-like traits.
The aryl moiety can be modified depending on whether DAT affinity is actually desirable or SERT affinity is wanted.
^ abRossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN978-0-9805790-9-3.edit
^Michaelis, Martin; Schölkens, Bernward; Rudolphi, Karl; Bermward Scholkens, Karl Rudolphi (April 2007). "An anthology from Naunyn-Schmiedeberg's archives of pharmacology". Naunyn-Schmiedeberg's Archives of Pharmacology (Springer Berlin) 375 (2): 81–84. doi:10.1007/s00210-007-0136-z. PMID17310263.Cite uses deprecated parameters (help)
^Kaiko, Robert F.; Kathleen M. Foley, Patricia Y. Grabinski, George Heidrich, Ada G. Rogers, Charles E. Inturrisi, Marcus M. Reidenberg (February 1983). "Central Nervous System Excitatory Effects of Meperidine in Cancer Patients". Annals of Neurology (Wiley Interscience) 13 (2): 180–185. doi:10.1002/ana.410130213. PMID6187275.Cite uses deprecated parameters (help)
^Baselt, R. (2008). Disposition of Toxic Drugs and Chemicals in Man (8 ed.). Foster City, CA: Biomedical Publications. pp. 911-914.
^Package insert for meperidine hydrochloride, Boehringer Ingelheim, Ridgefield, CT, 2005.
^Brody, Jane (February 27, 2007). "A Mix of Medicines That Can Be Lethal". New York Times. Retrieved 2009-02-13. "The death of Libby Zion, an 18-year-old college student, in a New York hospital on March 5, 1984, led to a highly publicized court battle and created a cause célèbre over the lack of supervision of inexperienced and overworked young doctors. But only much later did experts zero in on the preventable disorder that apparently led to Ms. Zion’s death: a form of drug poisoning called serotonin syndrome."
^Bronwen Bryant and Kathleen Knights (2010). Pharmacology for Health Professionals, 3rd Edition. Chatswood: Mosby Australia. ISBN978-0-7295-3929-6.
^Wagner, Larry E., II; Michael Eaton, Salas S. Sabnis, Kevin J. Gingrich (November 1999). "Meperidine and Lidocaine Block of Recombinant Voltage-Dependent Na+ Channels: Evidence that Meperidine is a Local Anesthetic". Anesthesiology (Lippincott Williams & Wilkins) 91 (5): 1481–1490. doi:10.1097/00000542-199911000-00042. PMID10551601.Cite uses deprecated parameters (help)
^ abcIzenwasser, Sari; Amy Hauck Newman, Brian M. Cox, Jonathan L. Katz (January/February 1996). "The cocaine-like behavioral effects of meperidine are mediated by activity at the dopamine transporter". European Journal of Pharmacology (Elsevier) 297 (1–2): 9–17. doi:10.1016/0014-2999(95)00696-6. PMID8851160.Cite uses deprecated parameters (help);Check date values in: |date= (help)
^Lomenzo, Stacey A.; Jill B. Rhoden, Sari Izzenwasser, Dean Wade, Theresa Kopajtic, Jonathan L. Katz, Mark L. Trudell (2005-03-05). "Synthesis and Biological Evaluation of Meperdine Analogs at Monoamine Transporters". Journal of Medicinal Chemistry (American Chemical Society) 48 (5): 1336–1343. doi:10.1021/jm0401614. PMID15743177.Cite uses deprecated parameters (help)
^ abcd"Demerol: Is It the Best Analgesic?" (PDF), Pennsylvania Patient Safety Reporting Service Patient Safety Advisory (Pennsylvania Patient Safety Authority) 3 (2), June 2006, retrieved 2013-04-15Cite uses deprecated parameters (help)
^ abcLatta, Kenneth S.; Brian Ginsberg, Robert L. Barkin (January/February 2002). "Meperidine: A Critical Review". American Journal of Therapeutics (Lippincott Williams & Wilkins) 9 (1): 53–68. doi:10.1097/00045391-200201000-00010. PMID11782820.Cite uses deprecated parameters (help);Check date values in: |date= (help)
^"In Brief". NPS Radar. National Prescribing Service. December 2005. Retrieved 2009-12-22.
^Walker, Diana J.; James P. Zacny (June 1999). "Subjective, Psychomotor, and Physiological Effects of Cumulative Doses of Opioid µ Agonists in Healthy Volunteers". The Journal of Pharmacology and Experimental Therapeutics (American Society for Pharmacology and Experimental Therapeutics) 289 (3): 1454–1464. PMID10336539.Cite uses deprecated parameters (help)
^Lomenzo, S.; Izenwasser, S.; Gerdes, R. M.; Katz, J. L.; Kopajtic, T.; Trudell, M. L. (1999). "Synthesis, dopamine and serotonin transporter binding affinities of novel analogues of meperidine". Bioorganic & Medicinal Chemistry Letters9 (23): 3273–3276. doi:10.1016/S0960-894X(99)00606-X.edit
^Rhoden, J. B.; Bouvet, M.; Izenwasser, S.; Wade, D.; Lomenzo, S. A.; Trudell, M. L. (2005). "Structure-activity studies of 3'-4'-dichloro-meperidine analogues at dopamine and serotonin transporters". Bioorganic & Medicinal Chemistry13 (19): 5623–5634. doi:10.1016/j.bmc.2005.05.025. PMID15993612.edit
^Millan, M. (2009). "Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs". Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics6 (1): 53–77. doi:10.1016/j.nurt.2008.10.039. PMID19110199. edit